Literature DB >> 33318300

Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma.

Tao Fan1,2, Mingchuang Zhu1,2, Liyu Wang2, Yu Liu2, He Tian2, Yujia Zheng2, Fengwei Tan2, Nan Sun2, Chunxiang Li2, Jie He1,2.   

Abstract

The composition and relative abundances of immune cells in the tumor microenvironment are key factors affecting the progression of lung adenocarcinomas (LUADs) and the efficacy of immunotherapy. Using the cancer gene expression dataset from The Cancer Genome Atlas (TCGA) program, we scored stromal and immune cells for tumor purity prediction by CIBERSORT and ESTMATE. Differential expression analysis was employed to identify 374 genes between the high-score group and the low-score group, which were utilized to conduct Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Protein-protein interaction (PPI) and Cox regression analysis were performed on the differentially expressed genes (DEGs) to identify four key tumor microenvironment (TME) -related genes (CCR2, CCR4, P2RY12, and P2RY13). The expression levels of the four DEGs differed significantly among LUAD patients of different ages, genders, and TNM stages. We found that the infiltration of resting memory CD4+ T cells, memory B cells, and M0 macrophages into the TME was co-regulated by these four DEGs. These four genes were closely related to the prognosis of LUAD and affected the infiltration of immune cells into the TME, which had predictive prognostic value in LUAD.

Entities:  

Keywords:  immune cell infiltration; lung adenocarcinoma; tumor immunity; tumor microenvironment; tumor stroma

Mesh:

Substances:

Year:  2020        PMID: 33318300      PMCID: PMC7880407          DOI: 10.18632/aging.202269

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  47 in total

1.  Immunotherapy: The path to win the war on cancer?

Authors:  Suzanne L Topalian; Jedd D Wolchok; Timothy A Chan; Ira Mellman; Karolina Palucka; Jacques Banchereau; Steven A Rosenberg; K Dane Wittrup
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

2.  Tumor Purity as an Underlying Key Factor in Glioma.

Authors:  Chuanbao Zhang; Wen Cheng; Xiufang Ren; Zheng Wang; Xing Liu; Guanzhang Li; Sheng Han; Tao Jiang; Anhua Wu
Journal:  Clin Cancer Res       Date:  2017-07-28       Impact factor: 12.531

3.  Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.

Authors:  Man Liu; Jingying Zhou; Xiaoyu Liu; Yu Feng; Weiqin Yang; Feng Wu; Otto Ka-Wing Cheung; Hanyong Sun; Xuezhen Zeng; Wenshu Tang; Myth T S Mok; John Wong; Philip Chun Yeung; Paul Bo San Lai; Zhiwei Chen; Hongchuan Jin; Jie Chen; Stephen Lam Chan; Anthony W H Chan; Ka Fai To; Joseph J Y Sung; Minhu Chen; Alfred Sze-Lok Cheng
Journal:  Gut       Date:  2019-05-10       Impact factor: 23.059

4.  CXCL5 as Regulator of Neutrophil Function in Cutaneous Melanoma.

Authors:  Agnes Forsthuber; Katharina Lipp; Liisa Andersen; Stefanie Ebersberger; 'Osvaldo Graña-Castro; Wilfried Ellmeier; Peter Petzelbauer; Beate M Lichtenberger; Robert Loewe
Journal:  J Invest Dermatol       Date:  2018-10-04       Impact factor: 8.551

Review 5.  Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy.

Authors:  Haseeb Zubair; Mohammad Aslam Khan; Shashi Anand; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Semin Cancer Biol       Date:  2020-05-26       Impact factor: 15.707

6.  Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma.

Authors:  Dimitra Kerdidani; Panagiotis Chouvardas; Ares Rocanin Arjo; Ioanna Giopanou; Giannoula Ntaliarda; Yu Amanda Guo; Mary Tsikitis; Georgios Kazamias; Konstantinos Potaris; Georgios T Stathopoulos; Spyros Zakynthinos; Ioannis Kalomenidis; Vassili Soumelis; George Kollias; Maria Tsoumakidou
Journal:  Nat Commun       Date:  2019-03-29       Impact factor: 14.919

7.  Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation.

Authors:  Leah Schmidt; Banu Eskiocak; Ryan Kohn; Celeste Dang; Nikhil S Joshi; Michel DuPage; Da-Yae Lee; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-13       Impact factor: 11.205

8.  Integrated analysis of dysregulated long non-coding RNAs/microRNAs/mRNAs in metastasis of lung adenocarcinoma.

Authors:  Lifeng Li; Mengle Peng; Wenhua Xue; Zhirui Fan; Tian Wang; Jingyao Lian; Yunkai Zhai; Wenping Lian; Dongchun Qin; Jie Zhao
Journal:  J Transl Med       Date:  2018-12-27       Impact factor: 5.531

9.  Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.

Authors:  Meng Zhou; Hengqiang Zhao; Zhenzhen Wang; Liang Cheng; Lei Yang; Hongbo Shi; Haixiu Yang; Jie Sun
Journal:  J Exp Clin Cancer Res       Date:  2015-09-11

10.  Establishment and Evaluation of a 6-Gene Survival Risk Assessment Model Related to Lung Adenocarcinoma Microenvironment.

Authors:  Zhitian Wang; Huiling Xu; Linhai Zhu; Tianyu He; Wang Lv; Zhigang Wu
Journal:  Biomed Res Int       Date:  2020-04-03       Impact factor: 3.411

View more
  10 in total

1.  Identification of P2RY13 as an immune-related prognostic biomarker in lung adenocarcinoma: A public database-based retrospective study.

Authors:  Jiang Lin; Chunlei Wu; Dehua Ma; Quanteng Hu
Journal:  PeerJ       Date:  2021-05-05       Impact factor: 2.984

2.  Identification of Tumor Microenvironment-Related Prognostic Genes in Sarcoma.

Authors:  Dongjun Dai; Lanyu Xie; Yongjie Shui; Jinfan Li; Qichun Wei
Journal:  Front Genet       Date:  2021-02-01       Impact factor: 4.599

3.  Immune-Related lncRNA Pairs as Prognostic Signature and Immune-Landscape Predictor in Lung Adenocarcinoma.

Authors:  Zhengrong Yin; Mei Zhou; Tingting Liao; Juanjuan Xu; Jinshuo Fan; Jingjing Deng; Yang Jin
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

4.  Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.

Authors:  Hang Chen; Wei Shen; Saiqi Ni; Menglu Sang; Shibo Wu; Yinyu Mu; Kaitai Liu; Ni Li; Linwen Zhu; Guodong Xu
Journal:  Aging (Albany NY)       Date:  2021-08-26       Impact factor: 5.682

Review 5.  P2Y12 Purinergic Receptor and Brain Tumors: Implications on Glioma Microenvironment.

Authors:  Fernanda Bueno Morrone; Pedro Vargas; Liliana Rockenbach; Thamiris Becker Scheffel
Journal:  Molecules       Date:  2021-10-12       Impact factor: 4.411

6.  The prognostic value of plasma complement factor B (CFB) in thyroid carcinoma.

Authors:  Pu Wu; Jinyuan Shi; Wei Sun; Hao Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

7.  Identification and Verification of Tumor Immune Microenvironment-Related Prognostic Genes in Kidney Renal Clear Cell Carcinoma.

Authors:  Gangcheng Kong; Yixuan Wang; Yuanjian Huang; Zhen Shi
Journal:  Biomed Res Int       Date:  2022-01-27       Impact factor: 3.411

8.  The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma.

Authors:  Xizhe Li; Ziyu Dai; Xianning Wu; Nan Zhang; Hao Zhang; Zeyu Wang; Xun Zhang; Xisong Liang; Peng Luo; Jian Zhang; Zaoqu Liu; Yanwu Zhou; Quan Cheng; Ruimin Chang
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

9.  Identification of Ubiquitin-Related Gene-Pair Signatures for Predicting Tumor Microenvironment Infiltration and Drug Sensitivity of Lung Adenocarcinoma.

Authors:  Yumei Li; Lanfen An; Zhe Jia; Jingxia Li; E Zhou; Feng Wu; Zhengrong Yin; Wei Geng; Tingting Liao; Wenjing Xiao; Jingjing Deng; Wenjuan Chen; Minglei Li; Yang Jin
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

Review 10.  Control of Macrophage Inflammation by P2Y Purinergic Receptors.

Authors:  Dominik Klaver; Martin Thurnher
Journal:  Cells       Date:  2021-05-04       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.